Worldwide, prominent pharmaceutical and biotechnology companies such as Tissue Tech Inc., Helixmith Co., Ltd., Oneness Biotech Co., Ltd., Ticeba GmbH, RHEACELL GmbH & Co. KG, and Lakewood-Amedex Inc., among others, are vigorously engaged in the development of drugs for diabetic foot ulcers. The emerging therapies currently in development are anticipated to offer effective treatment options with innovative mechanisms of action for patients suffering from diabetic foot ulcers.
DelveInsight’s, “Diabetic Foot Ulcers – Pipeline Insight, 2024,” report provides comprehensive insights about 23+ companies and 25+ pipeline drugs in Diabetic Foot Ulcers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The Diabetic Foot Ulcers Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Diabetic Foot Ulcers Overview
Diabetic Foot Ulcers is an open sore or wound that occurs among the most common complications of patients who have diabetes mellitus which is not well controlled. It occurs in approximately 15 percent of patients with diabetes, and is commonly located on the bottom of the foot, leading to lower extremity amputation. A diabetic foot ulcer is a skin sore with full thickness skin loss often preceded by a haemorrhagic subepidermal blister. The ulcer typically develops within a callosity on a pressure site, with a circular punched out appearance. It is often painless, leading to a delay in presentation to a health professional.
The pathophysiology of diabetic foot ulcers is multifaceted, involving neuropathic, vascular, and immune system components, all interconnected by the hyperglycemic state characteristic of diabetes. Elevated levels of glucose in the bloodstream contribute to oxidative stress, damaging nerve cells and resulting in neuropathy. Neuropathy diminishes sensation in the feet, making individuals less aware of trauma and injury, thus increasing the risk of developing ulcers. Concurrently, hyperglycemia affects blood vessels, leading to impaired circulation and compromised wound healing. Reduced blood flow deprives tissues of oxygen and nutrients necessary for healing, exacerbating ulcer formation and delaying recovery. Furthermore, the hyperglycemic environment impairs the immune response, compromising the body’s ability to fight infection and promote wound healing.
The most common signs and symptoms of diabetic foot ulcers include unusual swelling and redness, drainage on socks or in shoes, discoloration of the skin around the wound, blisters, corns and calluses, fever and chills. Ulcers often form under the big toes and at the bottom of feet due to trauma, poorly fitting shoes, poor blood flow, increased pressure, and nerve damage. In the early stages, there may be irritation, swelling, warmth, and discharge from the affected area.
The primary goal in the treatment of foot ulcers is to obtain healing as soon as possible. The management of diabetic foot ulcers requires offloading the wound, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic administration with or without surgical intervention if osteomyelitis or soft tissue infection is present, optimal control of blood glucose, and evaluation and correction of peripheral arterial insufficiency. The typical outpatient antibiotics regimen includes oral cephalosporins, and amoxicillin-clavulanic acid combination, (If MRSA is not of concern).
Diabetic Foot Ulcers Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Diabetic Foot Ulcers and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Diabetic Foot Ulcers market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Diabetic Foot Ulcers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
Molecule Type
Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Mechanism of the Emerging Pipeline Therapies
-
Beta 1 adrenergic receptor antagonists
-
Bacterial biofilm inhibitor
-
Peptide hydrolase replacements
-
Protein replacements
-
Angiogenesis inducing agent
-
Cell replacements
-
Type 5 cyclic nucleotide phosphodiesterase inhibitor
Learn How the Ongoing Clinical & Commercial Activities will Affect the Diabetic Foot Ulcers Therapeutic Segment
Diabetic Foot Ulcers Therapeutics Landscape
The main objective in treating foot ulcers is to achieve rapid healing. Managing diabetic foot ulcers involves offloading the wound, using daily saline or similar dressings to maintain a moist wound environment, performing debridement as needed, administering antibiotics with or without surgical intervention in cases of osteomyelitis or soft tissue infection, optimizing blood glucose control, and assessing and addressing peripheral arterial insufficiency.
To enhance the treatment landscape further, numerous major pharmaceutical and biotechnology companies are working on therapies for diabetic foot ulcers. Currently, Charsire Biotechnology Corporation is at the forefront of the therapeutics market with its diabetic foot ulcer drug candidates in the most advanced stages of clinical development.
Leading Companies in the Diabetic Foot Ulcers Therapeutics Market Include:
-
Amniox (TissueTech)
-
APstem Therapeutics
-
Aurealis Therapeutics
-
Beyond Air
-
Biotherapy Services
-
Charsire Biotechnology Corporation
-
Chiesi Farmaceutici
-
Helixmith (formerly known as ViroMed)
-
Lakewood-Amedex
-
Mallinckrodt
-
Microbion Corporation
-
NovaLead Pharma
-
Oneness Biotech
-
Rheacell (a subsidiary of Ticeba)
-
Roche
-
ShangHai HaiHe Pharmaceutical
-
TaiGen Biotechnology
-
Technophage
-
Transwell Biotech
-
ZZ Biotech
And Many Others
Diabetic Foot Ulcers Emerging and Marketed Drugs Covered in the Report Include:
-
Allo-APZ2-DFU (ABCB5 positive MSCs): Rheacell (a subsidiary of Ticeba)
-
AUP1602-C: Aurealis Therapeutics
-
Bisphosphocin Nu-3: Lakewood-Amedex
-
CSTC 1: Charsire Biotechnology Corporation
-
Engensis (VM202; Donaperminogene Seltoplasmid): Helixmith (formerly known as ViroMed)
-
ExpressGraft (C9T1 Skin Tissue): Mallinckrodt
-
MBN-101 (Pravibismane): Microbion Corporation
-
ON101 (WH-1): Oneness Biotech
-
RAPID Biodynamic Platelet Rich Plasma Haematogel: Biotherapy Services
-
TTAX01 (Neox Cord 1K): Amniox (TissueTech)
And Many More
Request the Sample PDF to Get a Better Understanding of the Diabetic Foot Ulcers Emerging Drugs and Key Companies
Table of Contents
1. Report Introduction
2. Executive Summary
3. Diabetic Foot Ulcers Current Treatment Patterns
4. Diabetic Foot Ulcers – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Diabetic Foot Ulcers Late Stage Products (Phase-III)
7. Diabetic Foot Ulcers Mid-Stage Products (Phase-II)
8. Diabetic Foot Ulcers Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Diabetic Foot Ulcers Discontinued Products
13. Diabetic Foot Ulcers Product Profiles
14. Key Companies in the Diabetic Foot Ulcers Market
15. Key Products in the Diabetic Foot Ulcers Therapeutics Segment
16. Dormant and Discontinued Products
17. Diabetic Foot Ulcers Unmet Needs
18. Diabetic Foot Ulcers Future Perspectives
19. Diabetic Foot Ulcers Analyst Review
20. Appendix
21. Report Methodology
Download sample report @ https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-pipeline-insight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/